Excellent news for adults with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). #MultipleSclerosis
Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis - TipRanks.com
Sanofi SA (($SNY)), Sanofi (($DE:SNW)), Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi SA is conducting a study titled ‘A Randomized,...
www.tipranks.com
August 10, 2025 at 10:36 PM
Excellent news for adults with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). #MultipleSclerosis
nrSPMS sounds like me, I have not kept up with the acronyms.
Hopefully the trial goes well.
Hopefully the trial goes well.
August 11, 2025 at 2:59 AM
nrSPMS sounds like me, I have not kept up with the acronyms.
Hopefully the trial goes well.
Hopefully the trial goes well.
Stellungnahme des KKNMS zur EU-Zulassung von Cenrifki® (Tolebrutinib) für nrSPMS
21.07.2026 – Die Zulassung von Cenrifki® (Tolebrutinib) durch die Europäische
Kommission für die Behandlung der sekundär progredienten Multiplen Sklerose oh...
weiterlesen
21.07.2026 – Die Zulassung von Cenrifki® (Tolebrutinib) durch die Europäische
Kommission für die Behandlung der sekundär progredienten Multiplen Sklerose oh...
weiterlesen
July 22, 2026 at 4:54 PM
Stellungnahme des KKNMS zur EU-Zulassung von Cenrifki® (Tolebrutinib) für nrSPMS
21.07.2026 – Die Zulassung von Cenrifki® (Tolebrutinib) durch die Europäische
Kommission für die Behandlung der sekundär progredienten Multiplen Sklerose oh...
weiterlesen
21.07.2026 – Die Zulassung von Cenrifki® (Tolebrutinib) durch die Europäische
Kommission für die Behandlung der sekundär progredienten Multiplen Sklerose oh...
weiterlesen
The United Arab Emirates (UAE) approve Tolebrutinib (CENRIFKI®), and inhibitor of Bruton's tyrosine kinase (BTK) for non-relapsing secondary progressive multiple sclerosis (nrSPMS) pubmed.ncbi.nlm.nih.gov/41284222/
Tolebrutinib: First Approval - PubMed
Tolebrutinib (CENRIFKI<sup>®</sup>) is an orally available, brain-penetrant small molecule inhibitor of Bruton's tyrosine kinase (BTK) being developed by Sanofi for the treatment of multiple sclerosis (MS). On 26 August 2025, tolebrutinib received its first approval in the United Arab Emirates (UAE) …
pubmed.ncbi.nlm.nih.gov
November 24, 2025 at 10:39 PM
The United Arab Emirates (UAE) approve Tolebrutinib (CENRIFKI®), and inhibitor of Bruton's tyrosine kinase (BTK) for non-relapsing secondary progressive multiple sclerosis (nrSPMS) pubmed.ncbi.nlm.nih.gov/41284222/
How To Manage Memory Issues When You Have nrSPMS.
I got #MECFS in 07/22, eventually it´s #PostVacSyndrome, but that´s a diagnosis of exclusion, no way I could get to the Charité in Berlin or to the Marburg uni clinic.
health.clevelandclinic.org/managing-att...
@clevelandclinic.bsky.social
I got #MECFS in 07/22, eventually it´s #PostVacSyndrome, but that´s a diagnosis of exclusion, no way I could get to the Charité in Berlin or to the Marburg uni clinic.
health.clevelandclinic.org/managing-att...
@clevelandclinic.bsky.social
How To Manage Memory Issues When You Have nrSPMS
Up to 65% of people with MS experience some level of cognitive impairment. So, what can you do about it? A neurologist shares strategies for preserving your cognitive function.
health.clevelandclinic.org
March 27, 2026 at 6:34 AM
How To Manage Memory Issues When You Have nrSPMS.
I got #MECFS in 07/22, eventually it´s #PostVacSyndrome, but that´s a diagnosis of exclusion, no way I could get to the Charité in Berlin or to the Marburg uni clinic.
health.clevelandclinic.org/managing-att...
@clevelandclinic.bsky.social
I got #MECFS in 07/22, eventually it´s #PostVacSyndrome, but that´s a diagnosis of exclusion, no way I could get to the Charité in Berlin or to the Marburg uni clinic.
health.clevelandclinic.org/managing-att...
@clevelandclinic.bsky.social
It appears the FDA decision for tolebrutinib in non-relapsing SP-MS will be further delayed beyond the end of this month
www.sanofi.com/en/media-roo...
www.sanofi.com/en/media-roo...
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated...
www.sanofi.com
December 15, 2025 at 6:30 PM
It appears the FDA decision for tolebrutinib in non-relapsing SP-MS will be further delayed beyond the end of this month
www.sanofi.com/en/media-roo...
www.sanofi.com/en/media-roo...
#Cenrifki #SPMS #multiplesclerosis #relapsingmultiplesclerosis #Sanofi #disabilitytargetingmedicine #nrSPMS #disabilityprogression #EMA #CHMP #HERCULESstudy #MSrelateddisability #brainpenetrantBrutonstyrosinekinaseinhibitor #smoulderingneuroinflammation #SPMSwithoutrelapses
zurl.co/GD1h3
zurl.co/GD1h3
Cenrifki approved in EU for secondary progressive multiple sclerosis - PharmaTimes
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS
pharmatimes.com
June 23, 2026 at 12:43 PM
And the FDA 👇
"Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients..."
www.sanofi.com/en/media-roo...
"Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients..."
www.sanofi.com/en/media-roo...
April 24, 2026 at 2:30 PM
And the FDA 👇
"Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients..."
www.sanofi.com/en/media-roo...
"Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adult patients..."
www.sanofi.com/en/media-roo...